Upcoming event: Pharma China Annual Forum 2011 on April 8 in Shanghai
3/31/2011
Event: Pharma China Annual Forum 2011
Organizer: Pharma China
Sponsors: RDPAC, Frontier Healthcare, more TBD
Date: 9 AM to 5 PM, April 8, 2011
Venue: Rendezvous Merry Hotel Shanghai, China
Brochure:
PCAF-2011.pdfFees: CNY 3,800 for Pharma China subscribers, 10% discount for RDPAC members, others pay full fee of CNY 5,500
Contact: David Xue, Chief Representative, Pharma China
Tel: +86 13911325130
Notwithstanding all the challenges clouding its future, the Chinese pharmaceutical sector managed to post higher growth again in 2010. Official sources expect the overall output value of the Chinese pharmaceutical industry to reach CNY 1,256 billion in 2010, up 25% year on year (compared with 21% in 2009) and accounting for no less than 7% of the Chinese GDP. The Chinese drug market size in 2010, on the other hand, is expected to reach CNY 755.6 billion at the retail price level, up 22% year on year (up from 21% growth in 2009).
For many pharmaceutical MNCs, China is now is likely to become their largest foreign market within a few years. Moreover, China has recently become a favorite destination for innovative drug R&D and many big pharma MNCs are increasingly relocating and outsourcing their R&D to the country.
The rising importance of China prompted many leading MNCs to elevate the corporate status of their Chinese subsidiaries in 2010 to ensure reinforced HQ attention. To ensure faster growth, MNCs reversed decisively their past prudence for acquisition of Chinese firms and opened the floodgate of M&As late last year with a flurry of major deals.
Nevertheless, the pharmaceutical industry in China continues to face mounting challenges and the country's ever-changing legal, regulatory and market environments of China's healthcare sector continues to pose the single biggest challenge to foreign companies. Deepening Chinese healthcare reform is reshaping the industry landscape, changing market dynamics and impacting the business models of multinational pharmaceutical companies in the country.
Meanwhile, China's drug regulation regime has continued to evolve in search of better solutions to secure drug safety and efficacy while containing costs, fostering innovation and supporting industry development.
Following China's WTO entry in 2002, the country has been moving its intellectual property rights regime closer to those found in many more developed nations. Despite the substantial progress made in this area, a number of issues continued to remain. On the other hand, as China's legal system evolves and becomes more mature, the Chinese population has become increasingly aware of their patient rights, leading to a growing number of lawsuits and a more challenging legal environment for pharma companies.
The Pharma China Annual Forum 2011 is an English language annual pharma industry event oriented for foreign drug companies in China. Due to the event's popularity in the past few years, we have expanded it into a full-day program this year. The event seeks to provide insights into new healthcare policies and drug regulations, discuss potential impacts of upcoming changes on the pharma industry (in particular foreign drug companies), draw attention to the emerging legal and IP issues, review M&A and industry consolidation trends, examine R&D and licensing trends, and improve vision for the future.
Ten leading experts will share their knowledge, insights and expertise in contemporary market trends, healthcare reform and policy direction, drug regulation and IP/legal issues. The presentation will be followed by an interactive panel discussion with speakers and other experts.
Sponsorship opportunities
Please contact us about sponsorship packages for refreshments and after-event cocktail.
Registration
Spaces are limited to 60 participants and priority is given to Pharma China subscribers. Please contact:
David Xue
Tel: +86 10 8530-0937 Cell: +86 13911325130
Fax: +86 10 8530-0938 Email: dxue@pharmaguys.com
Jenny Wang
Tel: +86 10 8447-6010